



CONNECTING LIFE AND SCIENCE

# Clinical Experience with Knowledge-Based Planning

*Lindsey Olsen, M.S.*  
*Washington University in St. Louis*



# Disclosures

- **Speaker Agreement with Varian Medical Systems**
- **License Agreement with Varian Medical Systems**

# Learning Objectives

- 1. Highlight the motivation for knowledge-based planning**
- 2. Describe the clinical indication for KBP**
- 3. Emphasize the importance of proper KBP model training and validation**

# Learning Objectives

- 1. Highlight the motivation for knowledge-based planning**
- 2. Describe the clinical indication for KBP**
- 3. Emphasize the importance of proper KBP model training and validation**

# Motivation


- **Why Knowledge-Based Planning?**
  - Leverage prior clinical and planning experience
  - Minimize repetition
  - Decision support (clinical sanity check)
  - Improve quality, efficiency, and automation

# Motivation


## Do IMRT planning goals guarantee optimal plans?

		Bilateral Neck Treatment	Ipsilateral Neck Treatment
<b>H&amp;N</b>	<b>PTV</b>	95% of PTV > 95% of Rx; Max dose < 110% of Rx	95% of PTV > 95% of Rx; Max dose < 110% of Rx
	<b>Spinal Cord</b>	Max dose 40 Gy	Max dose 40 Gy
	<b>Spinal Cord + Margin</b>	Max dose 52 Gy; < 1% (or 1 cc) exceeds 50 Gy	Max dose 52 Gy; < 1% (or 1 cc) exceeds 50 Gy
	<b>Optic Nerves, Optic Chiasm</b>	Max dose 54 Gy	Max dose 54 Gy
	<b>Brainstem</b>	Max dose 54 Gy; < 1% exceeds 60 Gy	Max dose 54 Gy; < 1% exceeds 60 Gy
	<b>Brain</b>	Max dose 60 Gy; < 1% exceeds 65 Gy	Max dose 60 Gy; < 1% exceeds 65 Gy
	<b>Retina</b>	Max dose 50 Gy; < 5% exceeds 45 Gy	Max dose 50 Gy; < 5% exceeds 45 Gy
	<b>Larynx</b>	As low as possible; mean dose < 45 Gy	As low as possible; mean Dose < 25 Gy
	<b>Upper Esophagus</b>	As low as possible; mean dose < 45 Gy	As low as possible; mean dose < 25 Gy
	<b>Parotid</b>	As low as possible; mean dose $\leq$ 26 Gy	As low as possible; mean dose $\leq$ 10 Gy (contralateral)
	<b>Pharyngeal Constrictors</b>	As low as possible; V60 < 60 Gy	As low as possible; V60 < 45 Gy
	<b>Submandibular</b>	As low as possible; mean dose < 39 Gy	As low as possible; mean dose < 24 Gy (contralateral)
<b>Oral Cavity</b>	As low as possible; mean dose < 35 Gy	As low as possible; mean dose < 20 Gy	
<b>Mandible</b>	Max 70 Gy; < 5% exceeds PTV Rx	Max 70 Gy; < 5% exceeds PTV Rx	
<b>Unspecified Tissue</b>	Less than PTV Rx; < 5% exceeds PTV Rx	Less than PTV Rx; < 5% exceeds PTV Rx	

# Motivation



# Motivation





# Motivation




## Practical Radiation Oncology

Volume 2, Issue 4, October–December 2012, Pages 296–305

### Variation in external beam treatment plan quality: An inter-institutional study of planners and planning systems


Benjamin E. Nelms PhD<sup>a,b,\*</sup>, Greg Robinson CMD<sup>c</sup>, Jay Markham CMD<sup>c</sup>,  
Kyle Velasco CMD<sup>c</sup>, Steve Boyd CMD<sup>c</sup>, Sharath Narayan CMD<sup>c</sup>,  
James Wheeler MD, PhD<sup>d</sup>, Mark L. Sobczak MD<sup>e</sup>





### Conclusions

There is a large inter-planner variation in plan quality as defined by a quantitative PQM score that measures the ability of the planner to meet very specific plan objectives. Plan quality was not statistically different between different TPS or delivery techniques and was not correlated to metrics of plan complexity, Certification and education demographics, experience, and confidence level of the planner were not good predictors of plan quality.

# Motivation




Moore, K.L. *et al.* Experience-based quality control of clinical intensity-modulated radiotherapy planning, *Int J Radiat Oncol Biol Phys.* 81(2):545-551 (2011)




# In general...

- Significance of Knowledge-Based Planning



# In general...

- **Significance of Knowledge-Based Planning**



**Does KBP deliver these claims?**

# Question 1

In an inter-intuitional study it has been shown that the large inter-planner variation in plan quality

- 0% a. depends on the planner's experience
- 0% b. is a direct result of the TPS
- 0% c. is independent of planner's experience
- 0% d. depends on planner's certification level
- 0% e. is a direct result of the technique used

# Question 1

In an inter-institutional study it has been shown that the large inter-planner variation in plan quality

1. a. depends on the planner's experience
2. b. is a direct result of the TPS
3. c. is independent of planner's experience
4. d. depends on planner's certification level
5. e. is a direct result of the technique used

Answer: c. is independent of planner's experience


Reference: B. Nelms, et.al., Variation in external beam treatment plan quality: An inter-institutional study of planners and planning systems, Practical Radiation Oncology, Volume 2, Issue 4, 2012.

# Learning Objectives



1. Highlight the motivation for knowledge-based planning
- 2. Describe the clinical indication for KBP**
3. Emphasize the importance of proper KBP model training and validation

# Outside Clinic Study

“ RT datasets for 20 clinically treated prostate IMRT plans from an outside institution transferred to Wash U pDVH DICOM tool



**Export DICOM RT  
files from outside  
institution TPS**





**Import files into  
Wash U pDVH  
DICOM Tool**

Appenzoller L.M., et. al. Predictive DVH models developed at a large institution impact clinically relevant DVH parameters in IMRT plans at an unrelated radiotherapy facility, Oral presentation AAPM 2013.





# Outside Clinic Study

- “ Clinic specific pDVH model created using institution’s own data
  - “ Similar plan quality demonstrated for all patients
  - “ No indication for improvement of clinically treated plans



# Outside Clinic Study

- “ Comparison against validated Wash U prostate model showed large improvements possible for rectum DVHs and small improvements for bladder DVHs for all patients





# Outside Clinic Study

- “ Five worst patients identified by sum of residuals between clinical DVH and predicted DVH
- “ Quantify improvements in clinical rectum and bladder DVHs with knowledge of pDVHs by replanning five worst patients



**Replan five patients using optimization objectives exported from pDVH tool**





**Import replan dose matrix into DICOM tool and compare to original DVHs and pDVHs**

# Outside Clinic Study

“ All five patients replanned showed similar results...”

Average Reduction in V65 and V40 for Rectum and Bladder				
Organ	V65(orig)-V65(replan)	dV65	V40(orig)-V40(replan)	dV40
Rectum	4.8%±2.3%	0.9%±1.1%	17.9%±10.3%	0.7%±1.4%
Bladder	3.4%±2.1%	0.4%±0.5%	6.0%±2.8%	0.6%±0.9%




Appenzoller L.M., et. al. Predictive DVH models developed at a large institution impact clinically relevant DVH parameters in IMRT plans at an unrelated radiotherapy facility, Oral presentation AAPM 2013.

# Institutional Plan Quality Study

**Objective: To assess the impact of DVH prediction (pDVH) models and a standardized planning technique on post-operative endometrial IMRT treatment plan quality.**


# Institutional Plan Quality Study

**Objective: To assess the impact of DVH prediction (pDVH)\* models and a standardized planning technique on post-operative endometrial IMRT treatment plan quality.**



# Institutional Plan Quality Study

**Objective: To assess the impact of DVH prediction (pDVH)\* models and a standardized planning technique on post-operative endometrial IMRT treatment plan quality.**



Olsen et al, "Impact of DVH prediction models and a standardized planning technique on post-op endometrial IMRT plan quality." ESTRO 2014.



# Results

- The impact of using pDVH models and a standard planning technique is demonstrated by plan quality improvement in the 5 patient validation cohort as seen by a reduction in V40 and mean dose for all OARs compared with the original clinical plan

OAR	25 Patient Training Cohort		
	SR	V40(orig)-V40(replan)	Mean(orig)-Mean(replan)
		(%)	(Gy)
Bladder	0.006 ± 0.045	8.8 ± 7.9	2.5 ± 1.7
Bowel	0.017 ± 0.023	2.7 ± 2.4	2.4 ± 1.6
Rectum	-0.007 ± 0.048	8.3 ± 8.8	3.2 ± 2.4
Sigmoid	-0.012 ± 0.056	12.3 ± 13.9	3.5 ± 2.8

OAR	5 Patient Validation Cohort			
	V40(orig)-V40(replan)	Mean(orig)-Mean(replan)	d_V40	d_mean
	(%)	(Gy)	(%)	(Gy)
Bladder	9.8 ± 5.1	2.3 ± 1.5	0.6 ± 5.2	0.5 ± 0.9
Bowel	2.1 ± 2.1	0.5 ± 0.6	1.7 ± 1.4	0.5 ± 1.4
Rectum	9.3 ± 5.9	2.7 ± 3.4	1.8 ± 3.3	0.6 ± 1.1
Sigmoid	9.1 ± 14.8	1.8 ± 2.3	1.3 ± 5.4	0.4 ± 1.5



# Plan Quality Study Results


- The impact of using pDVH models and a standard planning technique is demonstrated by plan quality improvement in the 5 patient validation cohort as seen by a reduction in V40 and mean dose for all OARs compared with the original clinical plan

Ongoing prospective clinical trial at Wash U to assess impact on plan quality and efficiency.

OAR	$v_{40}(\text{orig}) - v_{40}(\text{replan})$	$\text{mean}(\text{orig}) - \text{mean}(\text{replan})$	$\sigma_{v_{40}}$	$\sigma_{\text{mean}}$
	(%)	(Gy)	(%)	(Gy)
<b>Bladder</b>	$9.8 \pm 5.1$	$2.3 \pm 1.5$	$0.6 \pm 5.2$	$0.5 \pm 0.9$
<b>Bowel</b>	$2.1 \pm 2.1$	$0.5 \pm 0.6$	$1.7 \pm 1.4$	$0.5 \pm 1.4$
<b>Rectum</b>	$9.3 \pm 5.9$	$2.7 \pm 3.4$	$1.8 \pm 3.3$	$0.6 \pm 1.1$
<b>Sigmoid</b>	$9.1 \pm 14.8$	$1.8 \pm 2.3$	$1.3 \pm 5.4$	$0.4 \pm 1.5$

# Multi-Institutional Study


- Secondary analysis of RTOG 0126



K.L. Moore et al, "Quantifying unnecessary normal tissue complication risks due to suboptimal planning: a secondary study on RTOG0126 ." IJROBP, 2015.

# Multi-Institutional Study Results

- Results suggest decreased risk based on NTCP models



K.L. Moore et al, "Quantifying unnecessary normal tissue complication risks due to suboptimal planning: a secondary study on RTOG0126 ." IJROBP, 2015.

# What Have We Learned?

- Treatment plan quality variability is a problem.
  - At Washington University in St. Louis
  - At independent clinics
  - At many of the academic and independent clinics that enrolled patients on RTOG 0126
- Does KBP/auto-planning address these issues?
  - Improves ability to systematically achieve high quality plan
  - Improves efficiency of treatment plan generation
  - Necessary to benchmark models against other institutions

## Question 2

Several published studies have demonstrated that knowledge-based planning models

- 0% a. are helpful QC for structure delineation
- 0% b. can aid in plan quality improvement
- 0% c. should never be used by a rad onc
- 0% d. should only be used by a physicist
- 0% e. are IMRT optimization algorithms

## Question 2

Several published studies have demonstrated that knowledge-based planning models

- a. are helpful QC for structure delineation
- b. can aid in plan quality improvement
- a. should never be used by a rad onc
- b. should only be used by a physicist
- c. are IMRT optimization algorithms

Answer: b. can aid in plan quality improvement

Reference: L.M. Appenzoller, et. al., Predictive DVH models developed at a large institution impact clinical relevant DVH parameters in IMRT plans at an unrelated radiotherapy facility, Med. Phys. 40, 386 (2013).

# Learning Objectives

1. Highlight the motivation for knowledge-based planning
2. Describe the clinical indication for KBP
- 3. Emphasize the importance of proper KBP model training and validation**

# Model Training and Validation

- Importance of systematic KBP model training and validation process:

Quality of KBP  
Model



Quality of Plan  
Created with  
KBP Model



# Training and Validation Process


- Patient selection
- Model training and evaluation
- Model validation
- Clinical use of model

# Training and Validation Process

- Patient selection
- Model training and evaluation
- Model validation
- Clinical use of model

# Patient Selection: Geometry

- PTV / OAR Geometry
  - Similar target shape
  - Similar target location
  - Similar relative position of OARs to PTV
- CCMB ex.



Courtesy of J. Alpuche

# Patient Selection: Guidelines

- Similar Clinical Objectives
  - Same PTV coverage/OAR sparing criteria
- Similar Clinical Trade-Offs
  - Importance of PTV coverage / OAR sparing
- PTV prescription dose can vary
  - Estimated DVHs will be scaled as a percentage of Rx dose

		Bilateral Neck Treatment	Ipsilateral Neck Treatment
H&N	PTV	95% of PTV > 95% of Rx; Max dose < 110% of Rx	95% of PTV > 95% of Rx; Max dose < 110% of Rx
	Spinal Cord	Max dose 40 Gy	Max dose 40 Gy
	Spinal Cord + Margin	Max dose 52 Gy; < 1% (or 1 cc) exceeds 50 Gy	Max dose 52 Gy; < 1% (or 1 cc) exceeds 50 Gy
	Optic Nerves, Optic Chiasm	Max dose 54 Gy	Max dose 54 Gy
	Brainstem	Max dose 54 Gy; < 1% exceeds 60 Gy	Max dose 54 Gy; < 1% exceeds 60 Gy
	Brain	Max dose 60 Gy; < 1% exceeds 65 Gy	Max dose 60 Gy; < 1% exceeds 65 Gy
	Retina	Max dose 50 Gy; < 5% exceeds 45 Gy	Max dose 50 Gy; < 5% exceeds 45 Gy
	Larynx	As low as possible; mean dose < 45 Gy	As low as possible; mean Dose < 25 Gy
	Upper Esophagus	As low as possible; mean dose < 45 Gy	As low as possible; mean dose < 25 Gy
	Parotid	As low as possible; mean dose $\leq$ 26 Gy	As low as possible; mean dose $\leq$ 10 Gy (contralateral)
	Pharyngeal Constrictors	As low as possible; V60 < 60 Gy	As low as possible; V60 < 45 Gy
	Submandibular	As low as possible; mean dose < 39 Gy	As low as possible; mean dose < 24 Gy (contralateral)
	Oral Cavity	As low as possible; mean dose < 35 Gy	As low as possible; mean dose < 20 Gy
Mandible	Max 70 Gy; < 5% exceeds PTV Rx	Max 70 Gy; < 5% exceeds PTV Rx	
Unspecified Tissue	Less than PTV Rx; < 5% exceeds PTV Rx	Less than PTV Rx; < 5% exceeds PTV Rx	

# Patient Selection: Patient Numbers

- Number of training patients increases as the model complexity increases.
- Model validation process is used to ensure the number of training patients is sufficient




# Patient Selection: Plan Quality

- Training set plan quality
  - Output of KBP model directly correlated to input
  - Statistical noise present in KBP training set can impact model behavior
- QA of training set
  - Clinically approved, safe treatment
  - Consider iterative process in model training to obtain adequate model


# Plan Quality Considerations

- Ex. Prostate and Node model: OAR = Rectum
  - Poor correlation between actual and estimated DVH principal components for model trained with 70 mixed quality treatment plans



# Plan Quality Considerations

- Ex. Prostate and Node model: OAR = Rectum
  - Good correlation between actual and estimated DVH principal components for model trained with 48 good quality treatment plans





# Training and Validation Process

- Patient selection
- Model training and evaluation
- Model validation
- Clinical use of model

# Model Training and Evaluation

- “ Review the model statistical results
- “ Review the clinical vs. estimated DVHs
- “ Review model outliers
  - “ Geometric and dosimetric

**Note:** Will discuss model evaluation and validation in context of Varian RapidPlan™. Specific steps will differ depending on algorithm and implementation of KBP software.

# Review Model Statistics

- “ Assess model over-fitting
- “ Assess predictive ability of the model


```
Estimation model statistics for structure Rectum:
Model goodness of fit
DVH's principal components average fit 0.998977 out of 1.0
GED's principal components average fit 0.999374 out of 1.0
Regression model parameters: coefficient of determination 0.772767 out of 1.0
Regression model's parameters average chi square 1.14286
Whole estimation model's fit 0.771493 out of 1.0
Whole estimation model's average MSE 17.4678
Model goodness of estimation
Mean squared error between original and estimate 0.00237184
Statistics outside boundaries:
Proportion of histogram bins outside boundaries 40.4178
Mean of absolute deviation of bins outside boundaries -0.00248895
Mean squared error of bins outside boundaries 0.000618992
Standard deviation of the error of bins outside boundaries 0.0132559
Mean of the error of bins outside boundaries 0.0118805

Model was successfully trained with 41 out of 41 plans.

Model training done
```

# Review Clinical vs. Estimated DVHs


“ Model properly identifies variation in training set DVHs





# Review Clinical vs. Estimated DVHs

- “ Clinical DVH  $>$  estimate  $\rightarrow$  Outlier
- “ Clinically relevant parameter



# Identify and Remove Outliers

- Dosimetric outlier
  - Clinical DVH substantially differs from estimated DVH based on a clinically significant parameter
- Geometric outlier
  - PTV volume/shape substantially differs from the majority of the training set
  - Structure volume/shape substantially differs from the majority of the training set
  - Positional relationship between structure and PTV substantially differs from the majority of the training set

# Steps to Improve Model Quality

1. Add patients to address over-fitting
2. Remove geometric outliers or add similar patients
3. Remove or re-plan dosimetric outliers

# Steps to Improve Model Quality

1. Add patients to address over-fitting
2. Remove geometric or dissymmetric outlier
3. Remove outliers

**Iterative process**



# Question 3

In statistical modeling, an outlier is defined as..

- 0% a. a data point explained by the statistical model
- 0% b. a data analysis technique
- 0% c. a data point distant from other observations
- 0% d. an application that takes input and generates output
- 0% e. a method of understanding messages in the data

# Question 3

In statistical modeling, an outlier is defined as..

- a. a data point explained by the statistical model
- b. a data analysis technique
- c. a data point distant from other observations
- d. an application that takes input and generates output
- e. a method of understanding messages in the data

**Answer: c. a data point distant from other observations**

Reference: Boris Iglewicz and David Hoaglin (1993), %Volume 16: How to Detect and Handle Outliers+, The ASQC Basic References in Quality Control: Statistical Techniques, Edward F. Mykytka, Ph.D., Editor.

# Training and Validation Process


- Patient selection
- Model training and evaluation
- **Model validation**
- Clinical use of model

# Validation Patients

- “ Independent from patients used to train model
- “ Represent the range of patient geometries, plan geometries, and plan prescriptions for which the model will be clinically used
- “ Good plan quality
  - “ PTV coverage
  - “ OAR sparing

# Clinical vs. Estimated DVHs

- “ Review that clinically approved plan is within DVH estimation range
- “ If it is not, it is possible that plan can be improved



# Create Validation Plan w/ Model

Optimization - 031, (031) / Validation / Validation FOR NON-CLINICAL USE ONLY

Estimate DVH Plan Information

Add gEUD

	Vol[cm <sup>3</sup> ]	Vol [%]	Dose[Gy]	Actual Dose[Gy]	Priority	gEUD a
<input checked="" type="checkbox"/> PTV	179.7					
Upper	0.0	0.0	83.9	83.9	120	x
Lower	179.7	100.0	81.6	72.8	120	x
<input checked="" type="checkbox"/> BLADDER	84.6					
Upper	27.4	32.4	65.0	67.8	35	x
Upper	46.5	55.0	40.0	46.7	35	x
Upper	66.7	78.8	20.0	25.1	35	x
Upper	0.0	0.0	82.4	83.9	35	x
Line	83.8				35	x
<input checked="" type="checkbox"/> LT FEM HEAD	164.1					
Upper	0.0	0.0	40.0	47.6	35	x
<input checked="" type="checkbox"/> RECTUM	86.3					
Upper	6.0	6.9	65.0	76.7	35	x
Upper	16.4	19.0	40.0	47.9	35	x
Upper	35.3	40.9	20.0	23.1	35	x
Upper	0.0	0.0	82.4	83.4	35	x
Line	85.4				35	x
<input checked="" type="checkbox"/> RT FEM HEAD	155.7					
Upper	0.0	0.0	40.0	52.1	35	x
<input checked="" type="checkbox"/> SKIN RIND	2201.2					
Upper	0.0	0.0	40.0	48.6	35	x

Normal Tissue Objective: 100/Automatic NTO

Base Dose Plan: None

Settings: 1500/720s/Normal (2.5 mm)

Automatic Optimization Mode  Start IMRT Optimization  Intermediate Dose

Automatic Intermediate Dose

3D Dose Max: 83.9 Gy  
 3D MAX for PTV: 83.9 Gy  
 3D MEAN for PTV: 81.8 Gy  
 3D MIN for PTV: 72.8 Gy  
 Elapsed Time: s  
 Iteration


Fluence   
 Intermediate Dose

Open Log...

OK Cancel

# Objective Selection

- IMRT objective selection
  - Ensures clinically acceptable plan that achieves model estimate
  - Based on prior clinical experience
  - Priorities and objectives tuned during model validation



Model Structures and Objectives					
Target	ID	Vol [%]	Dose	Priority	gEU
Yes	PTV	(PTV)			
	Upper	0.0	105.0 %	120	
	Lower	100.0	103.0 %	120	
	Bladder	(15900)			
	Upper	0.0	104.0 %	35	
	Upper (fixed dose, generated vol.)	Generated	80.0 %	35	
	Upper (fixed dose, generated vol.)	Generated	50.0 %	35	
	Upper (fixed dose, generated vol.)	Generated	25.0 %	35	
	Line	Generated	Generated	35	
	Femur_L	(24475)			
	Upper	0.0	50.0 %	35	
	Femur_R	(24475)			
	Upper	0.0	50.0 %	35	
	Normal Tissue Objective				

# Assess Clinical Acceptability

- “ Review validation plans as per normal institution clinical standards
- “ Isodose distribution
- “ Clinical guidelines (scorecard)
  - “ PTV coverage
  - “ Hotspots
  - “ Population-based OAR DVH cut-points
- “ Plan technical integrity



# Training and Validation Process

- Patient selection
- Model training and evaluation
- Model validation
- Clinical use of model

# Clinical Use of Model

- Do not venture far from your validation set
- Consider automation/standardized protocols
  - Beam arrangement
  - Contouring guidelines
  - Plan quality reports (scorecards)
- Develop guidelines for clinical use
  - When should I use the model?
  - When should I plan manually?

# Final Thoughts

- “ Proper model training and validation is necessary for the clinical use of knowledge-based planning models
  - “ Possibility for systematic errors
- “ KBP is an exciting advancement, with potential for future development
  - “ Potential to improve quality, efficiency, and standardization
  - “ Does not replace human/clinician judgment

# Acknowledgements

- ” **Sasa Mutic, Ph.D.**
- ” **Kevin Moore, Ph.D.**
- ” **James Kavanaugh, M.S.**
- ” **Jun Tan, Ph.D.**
- ” **Jorge Alpuche, Ph.D.**
- ” **Jackie Wu, Ph.D.**
- ” **Min Yang, C.M.D.**
- ” **Jeff Michalski, M.D.**

# Questions?



[www.siteman.wustl.edu](http://www.siteman.wustl.edu)